Array BioPharma to Present ARRY-520 / KSP Inhibitor Data at 2010 ASH Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will present data from a Phase 1 trial of KSP inhibitor ARRY-520 in patients with relapsed/refractory multiple myeloma at the 2010 Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida on Saturday, December 4, 2010.

The abstract can be accessed through the ASH website, www.hematology.org/Meetings/Annual-Meeting. The abstract title is provided below, however, please note that according to ASH policy, all data is embargoed until the time of the beginning of the presentation. The poster will be available as a PDF after it is presented on Array's website at www.arraybiopharma.com.

Event:

    2010 Annual Meeting of the American Society of Hematology

Poster:

A Phase 1/2 Trial of the KSP Inhibitor ARRY-520 in Relapsed/Refractory Multiple Myeloma (Publication #1959)

Date:

Saturday, December 4, 2010

Time:

5:30 – 7:30 p.m. E.T.

Location:

Orange County Convention Center, Hall A3/A4, Poster Board no.: I-939

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to www.arraybiopharma.com.



CONTACT:

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
[email protected]

KEYWORDS:   United States  North America  Colorado  Florida

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Oncology  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.